Daiichi Sankyo
WEBDaiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world.
Daiichi Sankyo - Wikipedia
WEBDaiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. [3]
Press Releases - Daiichi Sankyo US
WEB5 days ago · About Daiichi Sankyo Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and …
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main …
WEB5 days ago · Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease ...
About Us - Daiichi Sankyo
WEBDaiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in 29 countries/regions around the world.
Our Pipeline - Research & Development - Daiichi Sankyo
WEBJul 31, 2024 · Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
Passion for innovation. Compassion for patients. - Daiichi Sankyo …
WEBFor people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Company Profile - Daiichi-Sankyo US
WEBDaiichi Sankyo, Inc. is the U.S. arm of Tokyo-based Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group, which spans 20 countries.
Daiichi Sankyo and MSD’s ADC improves progression-free …
WEB4 days ago · Daiichi Sankyo and MSD (Merck & Co) have reported that the Phase III HERTHENA-Lung02 clinical trial of patritumab deruxtecan, an HER3-directed DXd antibody-drug conjugate (ADC) in patients with ...
Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets
WEB5 days ago · Merck and Daiichi Sankyo last year agreed to jointly develop and commercialize a trio of antibody-drug conjugates, including patritumab deruxtecan, in a deal worth up to $22 billion. The companies ...
Skip to content